At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.
We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience. Our focus on neuroscience, our deep scientific expertise and our courage to take risks make us leaders in the research and development of medicines to transform neuroscience to benefit society.
We came to Biogen to solve the unsolvable. We stay to create new possibilities and grow together. We work fearlessly and go beyond because we care deeply about making a difference and changing lives. All legitimate correspondence from a Biogen employee will come from “@biogen.com” or “@smartrecruiters.com” email accounts.
Maintaining healthy operations during the COVID-19 pandemic
Since the early days of the pandemic, employee safety and well-being have been a top priority for Biogen. We have put in place very clear measures aimed at maintaining critical work so that we can continue delivering lifesaving medicines to people around the world.
We have been meeting, and, in some cases, exceeding the official guidance to protect our essential workers. We are closely following the developments in this space and will continue to adjust our protocols as necessary based on local health authority guidelines.
Prioritizing Employee Health, Safety and Well-Being
We have a deep sense of gratitude to our essential workers in the labs and manufacturing facilities who have continued their work with strict safety measures in place. As we learn more about the COVID-19 virus and how to stay safe, we update protocols and keep our employees and contractors informed of the latest developments.
A significant portion of our colleagues have successfully worked from home and this way of working will continue for some time. We are also encouraging the use of flexible work arrangements so that employees can manage their individual situations and still be productive.
Ensuring Continuous Supply of Medicine to Patients
Since the beginning of the COVID-19 pandemic, we have continued to operate our manufacturing facilities and supply our therapies, including biosimilars in Europe, for people around the world who are living with serious diseases. While we do not anticipate any interruptions, we cannot exclude the possibility that the continuing efforts to contain the spread of COVID-19 may have an impact in the future on our ability to manufacture or supply our therapies in certain areas of the world.
Creating Effective Ways to Serve our Patients and the Medical Community
We continue to be focused on delivering vital medicine to patients. We have adopted new models and digital technologies to engage with each other, our external stakeholders and to support the needs of patients and the medical community. We have implemented several initiatives to advance this effort, including adapting the way we conduct clinical trials, virtualizing customer engagement practices and applying digital technologies to collaborate with patient groups and the medical community. We believe that, in some instances, this crisis can be a catalyst for change and for re-inventing the way we conduct business in service of patients and the medical community everywhere.
Read more about our support for global support for COVID-19 relief.
View all COVID-19 updates
You are now leaving Biogen’s corporate website.
Third Party Sites
Biogen assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site's endorsement of Biogen or this website.